on December 22, 2005
Published online before print December 22, 2005, doi: 10.1161/01.STR.0000199082.07317.43
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 2, 2005
From the Servizio di Neurologia (G.P.A.), Ospedale S. Orsola FBF, AFaR, Associazione Fatebenefratelli per la Ricerca, Brescia, Italy; Laboratory of Epidemiology Neuroimaging and Telemedicine (G.B.F.), IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Clinica Neurologica Università di Brescia (E.M.), Italy; and Divisione di Cardiologia I (F.C., E.O.), Humanitas Gavazzeni, Bergamo, Italy. * To whom correspondence should be addressed. E-mail: gpanzola{at}numerica.it.
Background and Purpose--Transcatheter closure of patent foramen ovale (PFO) has been reported to improve migraine in patients with cerebrovascular disorders in noncontrolled studies. The aim of the study was to compare the course of migraine assessed prospectively over a 12-month period in symptomatic (for cerebrovascular disease) and asymptomatic patients undergoing PFO closure and in patients with PFO treated medically. Methods--Twenty-three stroke symptomatic (SS; 39±10 years of age; males/females [M/F] 5/18) and 27 stroke asymptomatic (SA; 40±12 years of age; M/F 5/22) patients with migraine underwent PFO closure. Twenty-seven patients with migraine and PFO (controls [CTRLS]; 36±11 years of age; M/F 4/23) were followed up medically. Migraine severity was assessed at baseline with a scale that takes into account the frequency, duration, and intensity of the attacks and the occurrence of aura (score range 0 to 10). Six months later, the patients were given a structured diary to annotate monthly with the same scale the characteristics of the attacks for the next 6 months. By the end of 1 year, the migraine score was averaged for the last 6 months. Results--Baseline severity of migraine did not differ between groups (6.3 to 6.1 and 6.7 in SS, SA, and CTRLS groups, respectively). At the 1-year assessment, the overall migraine score had significantly improved by 3.7 and 2.8 points in SS and SA, respectively (P<0.001 on repeated-measure ANOVA), whereas it had nonsignificantly worsened by 0.1 points in CTRLS. Multiple linear regression analysis showed that the improvement in SS and SA was independent of migraine type, age, and cerebrovascular risk factors. Twenty-one of 21 patients with migraine with aura in the CTRLS group still had aura at the end of follow-up, whereas only 3 of 14 among SA and 4 of 19 among SS continued to have migraine preceded by aura (P<0.0001 on Fisher exact test). Conclusions--Compared with medical treatment, closure of PFO brings about a significant overall improvement in migraine. This seems to occur irrespective of migraine type and of previous cerebrovascular disease. In addition to the overall improvement, in migraine with aura, the occurrence of aura is dramatically reduced.
Revised on October 12, 2005
Accepted on November 2, 2005
Shunt-Associated Migraine Responds Favorably to Atrial Septal Repair. A Case-Control Study
Gian P. Anzola MD*;
Key words: foramen ovale, patent • migraine
This article has been cited by other articles:
 |
|
 |
|
  J. D. Carroll and E. P. Carroll Is patent foramen ovale closure indicated for migraine?: PFO Closure Is Not Indicated for Migraine: "Don't Shoot First, Ask Questions Later" Circ Cardiovasc Interv, October 1, 2009; 2(5): 475 - 481. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Meier Stroke and migraine: a cardiologist's headache Heart, April 1, 2009; 95(7): 595 - 602. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vigna, N. Marchese, V. Inchingolo, G. M. Giannatempo, M. A. Pacilli, P. Di Viesti, M. Impagliatelli, R. Natali, A. Russo, R. Fanelli, et al. Improvement of Migraine After Patent Foramen Ovale Percutaneous Closure in Patients With Subclinical Brain Lesions: A Case-Control Study J. Am. Coll. Cardiol. Intv., February 1, 2009; 2(2): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Wahl and B Meier Patent foramen ovale and ventricular septal defect closure Heart, January 1, 2009; 95(1): 70 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rundek, M. S.V. Elkind, M. R. Di Tullio, E. Carrera, Z. Jin, R. L. Sacco, and S. Homma Patent Foramen Ovale and Migraine: A Cross-Sectional Study From the Northern Manhattan Study (NOMAS) Circulation, September 30, 2008; 118(14): 1419 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dowson, M. J. Mullen, R. Peatfield, K. Muir, A. A. Khan, C. Wells, S. L. Lipscombe, T. Rees, J. V. De Giovanni, W. L. Morrison, et al. Migraine Intervention With STARFlex Technology (MIST) Trial: A Prospective, Multicenter, Double-Blind, Sham-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With STARFlex Septal Repair Implant to Resolve Refractory Migraine Headache Circulation, March 18, 2008; 117(11): 1397 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Di Legge and F. Sallustio Migraine Relief After Patent Foramen Ovale Closure: Should Vascular Risk Factor Control Be Achieved First? Stroke, December 1, 2006; 37(12): 2876 - 2876. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Post and W. Budts The Relationship Between Migraine and Right-to-Left Shunt: Fact or Fiction? Chest, September 1, 2006; 130(3): 896 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Gupta Interatrial Shunt-Associated Migraine: Serendipity, Empiricism, Hope, or Hype? Stroke, September 1, 2006; 37(9): 2212 - 2212. [Full Text] [PDF]
|
|
|
|
|
|
A. Magrini, L. Coppeta, A. Pietroiusti, G. Somma, E. Romeo, A. Bergamaschi, and M. Diomedi Shunt-Associated Migraines Respond Favorably to Changes in Work Conditions Stroke, June 1, 2006; 37(6): 1361 - 1361. [Full Text] [PDF]
|
|